Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688117.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688117.SS and 80,000+ other tickers.
See exactly how 688117.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688117.SS and 80,000+ other tickers.
ChengDu ShengNuo Biotec Co.,Ltd. focuses on the entire lifecycle of peptide pharmaceuticals, from initial research and development to manufacturing, and their subsequent domestic and international distribution. The company's product portfolio encompasses active polypeptide ingredients (APIs), solid dosage tablets, and a diverse range of injectable formats, including freeze-dried powders, small-volume solutions, pre-filled syringes, and specialized card-type injections. This enterprise was established in 2001 and conducts its operations from Chengdu, China.
No recent news available.